No­var­tis is eye­ing a multi­bil­lion-dol­lar Med­Co buy­out as Jer­sey biotech nears NDA — re­ports

To get from No­var­tis’ US head­quar­ters to the Med­i­cines Com­pa­ny, you make a left out of a square con­crete build­ing on NJ-Route 10, fol­low it past the sun or­ange ve­ran­da of Jer­sey’s Hot Bagels and the in­ex­plic­a­ble green Ver­mont cab­in that hous­es the Whip­pa­ny Rail­way Mu­se­um un­til you turn right and im­me­di­ate­ly ar­rive at a rec­tan­gu­lar glass build­ing. It should take you about 12 min­utes.

Re­ports are out that No­var­tis may be mak­ing that trip. Amid a tor­rent of Phase III da­ta bur­nish­ing Med­Co’s chances at a block­buster cho­les­terol drug,  Bloomberg News is re­port­ing that No­var­tis is look­ing to ac­quire the Jer­sey-based biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER